£15.48
12.59% today
London, Nov 06, 05:35 pm CET
ISIN
GB00B0LCW083
Symbol
HIK

Hikma Pharmaceuticals Stock price

£15.22
-3.15 17.15% 1M
-4.58 23.14% 6M
-4.06 21.07% YTD
-1.93 11.23% 1Y
+3.73 32.49% 3Y
-7.72 33.66% 5Y
-1.06 6.51% 10Y
+13.16 639.73% 20Y
London, Closing price Thu, Nov 06 2025
-2.49 14.06%
ISIN
GB00B0LCW083
Symbol
HIK
Industry

New AI Insights on Hikma Pharmaceuticals Insights AI Insights on Hikma Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
£3.9b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
13.8 | 9.9
P/S
1.6 | 1.5
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
£0.61
Yield 1Y | 5Y
3.5% | 2.5%
Growth 1Y | 5Y
24.3% | 12.6%
Payout 1Y | 3Y
49.9% | 60.6%
Increased
19 Years
Financials (TTM | estimate)
Revenue
£2.5b | £2.6b
EBITDA
£531.0m | £688.7m
EBIT
£461.3m | £560.9m
Net Income
£284.3m | -
Free Cash Flow
£174.7m
Growth (TTM | estimate)
Revenue
7.5% | 8.4%
EBITDA
-2.0% | 24.7%
EBIT
-2.4% | 16.4%
Net Income
30.2% | -
Free Cash Flow
-39.8%
Margin (TTM | estimate)
Gross
43.7%
EBITDA
21.4% | 26.3%
EBIT
18.6%
Net
11.4% | -
Free Cash Flow
7.0%
Financial Health
Equity Ratio
45.0%
Return on Equity
15.5%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
£1.3
FCF per Share
-
Short interest
50.0%
Employees
10k
Rev per Employee
£250.0k
Show more

Is Hikma Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Hikma Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Hikma Pharmaceuticals forecast:

17x Buy
85%
3x Hold
15%

Analyst Opinions

20 Analysts have issued a Hikma Pharmaceuticals forecast:

Buy
85%
Hold
15%

Financial data from Hikma Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,486 2,486
8% 8%
100%
- Direct Costs 1,401 1,401
15% 15%
56%
1,085 1,085
1% 1%
44%
- Selling and Administrative Expenses 434 434
0% 0%
17%
- Research and Development Expense 117 117
5% 5%
5%
531 531
2% 2%
21%
- Depreciation and Amortization 70 70
1% 1%
3%
EBIT (Operating Income) EBIT 461 461
2% 2%
19%
Net Profit 284 284
30% 30%
11%

In millions GBP.

Don't miss a Thing! We will send you all news about Hikma Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd. and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Riad Mishlawi
Employees 9,500
Founded 1978
Website www.hikma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today